[Middle-molecular hydroxyethyl starch as a volume substitute. Its rheological effect in peripheral arterial occlusive diseases].
The tolerance to and effectiveness of middle-molecular hydroxy-ethyl starch as volume replacement by isovolemic haemodilution over 6 weeks was tested in 15 patients with peripheral arterial obstructive disease, stages II and III. After 6 weeks of isovolemic haemodilution treatment the pain-free walking distance increased significantly, the peak-flow after reactive hyperaemia increased, blood pressure and pulse remained unchanged, blood fluidity was significantly improved. This pilot study indicates that middle-molecular hydroxy-ethyl starch as volume replacement through isovolemic haemodilution represents a good alternative to dextran. It may even be superior to dextran in the treatment of arterial obstructive disease.
D001157:Arterial Occlusive Diseases / Q000097:blood / Q000628:therapy*; D001809:Blood Viscosity / Q000187:drug effects*; D004341:Drug Evaluation; D005260:Female; D005684:Gait; D006438:Hemodilution; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D010952:Plasma Substitutes / Q000627:therapeutic use*; D013213:Starch / Q000031:analogs & derivatives*; D013997:Time Factors
D006895:Hydroxyethyl Starch Derivatives; D010952:Plasma Substitutes; D013213:Starch
Mittelmolekulare Hydroxyäthylstärke als Volumenersatzmittel. Rheologische Wirkung bei peripherer arterieller Verschlusskrankheit.